Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3145491 | 1.00 | CA5A (0.67) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL2009711 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL1938248 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL3531521 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL22499922 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL21907 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL226032 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL8523755 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL21294081 | 0.94 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL10582956 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751158-A4 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | BRISTOL MYERS SQUIBB CO (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1751158-A1 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | Brystol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005118585-A1 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-08 | — | — | US | claimed |
| US-7968555-B2 | Intermediates in the preparation of entecavir via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100286089-A1 | Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-11 | — | — | US | disclosed |
| US-7786300-B2 | Process for preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090143578-A1 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-04 | — | — | US | disclosed |
| EP-1751158-A4 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | BRISTOL MYERS SQUIBB CO (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7511139-B2 | Photodesilylation, oxidation, deportection, reaction with triisopropyl orthoformate in presence of acid catalyst, further reacting acetic anhydride and acetic acid, hydrolysis with HCl to form entecavir; aniviral agent; hepatitis b | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1751158-A1 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | Brystol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118585-A1 | PROCESS FOR THE PREPARATION OF ENTECAVIR AND NOVEL INTERMEDIATES THEREOF VIA CARBON-SILICON OXIDATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143578-A1 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | SAMHD1, TYMP, SORD | CA5A 1145/4885CA5B 914/4885TSHR 4708/4885 |
| US-20100286089-A1 | Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation | SAMHD1, TYMP, SEPTIN9 | CA5A 1486/4885CA5B 1252/4885TSHR 4709/4885 |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | SAMHD1, TYMP, SEPTIN9 | CA5A 1486/4885CA5B 1252/4885TSHR 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.